Abstract:Background & objectives: Despite the wide interest surrounding drug repurposing, no common terminology has been yet agreed for these products and their full potential value is not always recognised and rewarded, creating a disincentive for further development. The objectives of the present study were to assess from a wide perspective which value drug repurposing might bring to society, but also to identify key obstacles for adoption of these medicines and to discuss policy recommendations. Methods: A preliminary comprehensive search was conducted to assess how the concept of drug repurposing was described in the literature. Following completion of the literature review, a primary research was conducted to get perspective of various stakeholders across EU member states on drug repurposing (healthcare professionals, regulatory authorities and Health Technology Assessment (HTA) bodies/payers, patients, and representatives of the pharmaceutical industry developing medicines in this field). Ad hoc literature review was performed to illustrate, when appropriate, statements of the various stakeholders. Results: Various nomenclatures have been used to describe the concept of drug repurposing in the literature, with more or less broad definitions either based on outcomes, processes, or being a mix of both. In this context, Medicines for Europe (http://www.medicinesforeurope.com/value-added-medicines/) established one single terminology for these medicines, known as value added medicines, defined as 'medicines based on known molecules that address healthcare needs and deliver relevant improvements for patients, healthcare professionals and/or payers'. Stakeholder interviews highlighted three main potential benefits for value added medicines: (1) to address a number of medicine-related healthcare inefficiencies related to irrational use of medicines, non-availability of appropriate treatment options, shortage of mature products, geographical inequity in medicine access; (2) to improve healthcare system efficiency; and (3) to contribute to sustainability of healthcare systems through economic advantages. Current HTA framework, generic stigma, and pricing rules, such as internal reference pricing or tendering processes in place in some countries, were reported as the current key hurdles preventing the full recognition of value added medicines' benefits, discouraging manufacturers from bringing such products to the market. Discussion & conclusions: There is currently a gap between increasing regulatory authority interest in capturing value added medicines' benefits and the resistance of HTA bodies/payers, who tend to ignore this important segment of the pharmaceutical field. This situation calls for policy changes to foster appropriate incentives to enhance value recognition of value added medicines and deliver the expected benefit to society. Policy changes from HTA perspective should include: absence of any legislative barriers preventing companies from pursuing HTA; HTA requirements proportionate to potential reward; HTA decision-making framework taking into account the specific characteristics of value added medicines; eligibility for early HTA dialogues; Policy changes from pricing perspective should encompass: tenders/procurement policies allowing differentiation from generic medicines; eligibility for early entry agreement; non-systematic implementation of external and internal reference pricing policies; recognition of indication-specific pricing. At the same time, the pharmaceutical industry should engage all the stakeholders (patients, healthcare providers, HTA bodies/payers) in early dialogues to identify their expectations and to ensure the developed value added medicines address their needs.

Reimbursed Medication Adherence Enhancing Interventions in European Countries: Results of the EUREcA Study

Identifying and presenting key country-specific indicators related to medication adherence: a comprehensive study across European countries

Barriers and Unmet Educational Needs Regarding Implementation of Medication Adherence Management Across Europe: Insights from COST Action ENABLE

Systematic Review of Outcomes for Assessment of Medication Adherence Enhancing Interventions: An ISPOR Special Interest Group Report

Developing a medication adherence technologies repository: proposed structure and protocol for an online real-time Delphi study

Outcome-based reimbursement in Central-Eastern Europe and Middle-East

Cost-effectiveness and impact on healthcare utilization of interventions to improve medication adherence and outcomes in asthma and COPD: A systematic literature review

Implementing a Managed Entry Agreement Framework in Cyprus

Clinical aspects of reimbursement policies for orphan drugs in Central and Eastern European countries

A Review of Current Approaches to Evaluating and Reimbursing New Medicines in a Subset of OECD Countries

Digital Health Reimbursement Strategies of 8 European Countries and Israel: Scoping Review and Policy Mapping

Delayed payment schemes in Central-Eastern Europe and Middle-East

Adherence to chronic medication in older populations: application of a common protocol among three European cohorts

Implementation fidelity in a multifaceted program to foster rational antibiotics use in primary care: an observational study

Evaluation of medication safety assessment tools for pharmacist-led medication reviews: the Eastern European pilot project

Value added medicines: what value repurposed medicines might bring to society?

Importance of aligning the implementation of new payment models for innovative pharmaceuticals in European countries

Factors Facilitating and Hindering Development of a Medication Use Review Service in Eastern Europe and Iran-Cross-Sectional Exploratory Study

Innovative Approaches to Enhance and Measure Medication Adherence in Chronic Disease Management: A Review

Remote Monitoring of Chronic Diseases: A Landscape Assessment of Policies in Four European Countries

A Digital Intervention Using Daily Financial Incentives to Increase Medication Adherence in Severe Mental Illness: A Feasibility Study (Preprint)